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Abstract
Background: Sleep restriction is associated with development of metabolic ill-health, and hormonal mechanisms may
underlie these effects. The aim of this study was to determine the impact of short term sleep restriction on male health,
particularly glucose metabolism, by examining adrenocorticotropic hormone (ACTH), cortisol, glucose, insulin, triglycerides,
leptin, testosterone, and sex hormone binding globulin (SHBG).
Methodology/Principal Findings: N=14 healthy men (aged 27.463.8, BMI 23.562.9) underwent a laboratory-based sleep
restriction protocol consisting of 2 baseline nights of 10 h time in bed (TIB) (B1, B2; 22:00–08:00), followed by 5 nights of 4 h
TIB (SR1–SR5; 04:00–08:00) and a recovery night of 10 h TIB (R1; 22:00–08:00). Subjects were allowed to move freely inside
the laboratory; no strenuous activity was permitted during the study. Food intake was controlled, with subjects consuming
an average 2000 kcal/day. Blood was sampled through an indwelling catheter on B1 and SR5, at 09:00 (fasting) and then
every 2 hours from 10:00–20:00. On SR5 relative to B1, glucose (F1,168 = 25.3, p,0.001) and insulin (F1,168 = 12.2, p,0.001)
were increased, triglycerides (F1,168 = 7.5, p= 0.007) fell and there was no significant change in fasting homeostatic model
assessment (HOMA) determined insulin resistance (F1,168 = 1.3, p= 0.18). Also, cortisol (F1,168 = 10.2, p= 0.002) and leptin
(F1,168 = 10.7, p= 0.001) increased, sex hormone binding globulin (F1,167 = 12.1, p,0.001) fell and there were no significant
changes in ACTH (F1,168 = 0.3, p= 0.59) or total testosterone (F1,168 = 2.8, p= 0.089).
Conclusions/Significance: Sleep restriction impaired glucose, but improved lipid metabolism. This was associated with an
increase in afternoon cortisol, without significant changes in ACTH, suggesting enhanced adrenal reactivity. Increased
cortisol and reduced sex hormone binding globulin (SHBG) are both consistent with development of insulin resistance,
although hepatic insulin resistance calculated from fasting HOMA did not change significantly. Short term sleep curtailment
leads to changes in glucose metabolism and adrenal reactivity, which when experienced repeatedly may increase the risk
for type 2 diabetes.
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Introduction
Chronic sleep restriction is common due to occupational, social
and lifestyle demands and/or medical conditions [1]. In large
cross-sectional and cohort studies, self-reported short sleep
duration has been found to be related to metabolic disorders such
as insulin resistance [2], obesity [3–5], metabolic syndrome [6]
and type 2 diabetes [7–9]. Key features of such metabolic
disorders include development of insulin resistance, hyperglycemia
and hypertriglyceridemia. Indeed, alterations in insulin, glucose
and triglycerides are indicative of metabolic syndrome [10–14].
Recent controlled laboratory studies have investigated the causal
relationship between short sleep and metabolic health and have
generally reported impaired glucose tolerance and/or develop-
ment of insulin resistance after one to fourteen nights of four to six
hours of sleep restriction per day [15–21]. Considering the broad
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health implications this could have in today’s 24/7 society, there is
considerable interest in elucidating the hormonal mechanisms
underlying these sleep loss-related metabolic changes.
Sleep restriction impairs glucose tolerance [16,18]. Early studies
reported little change in circulating insulin with sleep restriction
[18,22], but subsequent studies have found that insulin increases
[15,16,20], particularly after breakfast [16]. Overall insulin
resistance has generally been found to worsen with sleep restriction
[15,23]. Little information exists on the effects of sleep restriction
on triglycerides or free fatty acids, which are converted from
triglycerides in many tissues. Fasting free fatty acids (FFA) show no
significant change after one night of sleep restriction [15] and
increase following two [16] nights of sleep restriction to 4 h TIB.
Cross-sectional data suggest a relationship between short sleep
duration and elevated triglycerides [24]. To date, the effect of
sleep restriction on triglycerides has only been experimentally
examined in women, with no significant change found following
three nights of 4 h time in bed (TIB) [25].
Cortisol, a stress hormone released by the adrenal axis, induces
gluconeogenesis, reduces peripheral glucose utilization, induces
insulin resistance and raises blood glucose concentrations [26].
Some studies showed that sleep restriction significantly increases
plasma cortisol levels during the late afternoon to early evening
hours [17,18], whereas others showed little to no changes
[16,21,23,27]. These conflicting results may be due to the
variations in physiological stress induced by the different forms
of sleep restriction (e.g. amount and timing of sleep), invasiveness
of the tests used during the study (e.g. insertion of indwelling
catheters, fasting, etc.) and the type of laboratory environment (e.g.
amount of social contact). Effects of sleep loss on the adrenal axis,
potentially as a stress response, is one hormonal mechanism by
which altered sleep could cause changes in glucose metabolism,
either directly acting on the adrenal gland or indirectly through
changes in pituitary hormones such as adrenocorticotropic
hormone (ACTH).
Leptin is an adipokine that acts as a satiety signal, and can
directly or indirectly improve insulin sensitivity and reduce lipids
and visceral adiposity [28]. Early studies investigating the
relationship between sleep restriction and leptin showed that sleep
restriction decreased leptin levels [17,19], and increased self-
reported appetite and hunger [19]. These data implicate reduced
leptin as a hormonal mechanism by which sleep restriction can
worsen insulin sensitivity, increase circulating lipids, and lead to
obesity and abdominal obesity via disruption of energy balance
and increased cravings for carbohydrate rich foods. Subsequent
studies have not consistently confirmed these earlier findings
[20,29–34], possibly due to differences in experimental protocols,
including whether subjects were kept in the laboratory for the
duration of the study period or allowed to leave during the day
[18,19,21]; ad libitum [29] versus controlled [35] versus restricted
food intake [17]; use of glucose tolerance tests in place of a
breakfast meal [17,19,23] which contributes to restricted or
abnormal eating patterns over the day; or whether subjects were
rested in bed during blood sampling [17,18,21]. Although more
data are needed under each of these unique conditions to elucidate
the impact sleep restriction has on leptin, it is widely considered a
candidate mechanism for the development of metabolic diseases
such as obesity and type 2 diabetes.
Testosterone is the quintessential anabolic hormone, vital for
masculinization, and responsible for increased muscle mass and
strength and reduced adiposity. Lowering testosterone has the
inverse effect on metabolic and body compositional parameters,
including increases of overall adiposity [36] and visceral fat
accumulation [37] and induction of insulin resistance as well as
decrease of resting metabolic rates. Both low testosterone [38–40]
and sex hormone binding globulin (SHBG) [41,42] are associated
with metabolic syndrome and insulin resistance. While observa-
tional studies have identified a relationship between total sleep
deprivation and reduced testosterone [43,44], only one experi-
mental laboratory based study has investigated the impact of
partial sleep restriction on testosterone [45]. It found a decrease in
afternoon and evening (14:00–22:00) plasma testosterone levels
after eight nights of sleep restriction to five hours per night.
No previous studies have examined the effect of sleep restriction
on SHBG, a hepatic glycoprotein primarily responsible for
transport of the sex hormones testosterone and estradiol [46].
Given associations between SHBG and metabolic functioning in
cohort studies [41,42], it may be important to examine the impact
of sleep restriction on SHBG. Remarkably, while most studies of
sleep restriction and metabolism have exclusively examined male
populations, the effects of sleep loss on the regulation of sex
hormones has received scant attention.
The overall aim of this study was to address gaps in knowledge
that still exist regarding sleep restriction and metabolism by
examining the effect of 5 nights of sleep restriction on glucose
metabolism and triglycerides, and to examine cortisol-, leptin- or
testosterone-based mechanisms that may underpin these changes
in healthy young men.
Materials and Methods
Ethics Statement
The study was approved by the University of South Australia
Human Research Ethics Committee. All subjects provided written
informed consent to participate in the study prior to entering the
laboratory. Study subjects were paid a modest honorarium for
their time.
Subjects
Sixteen healthy men aged 22–36 y (mean 6 SD; 27.463.8)
were recruited to the study. 28.6% were from racial/ethnic
minorities. Subjects reported habitual nocturnal sleep durations
between 7.0 h and 8.5 h (8.261.3) and habitually rose between
06:00 and 09:00. Subjects did not report habitual napping
(confirmed using actigraphy for a minimum 1 week prior to
participating in the study), or any complaints of insomnia, daytime
sleepiness, or other sleep-wake disturbances. Subjects completed
interviews, clinical history, questionnaires and blood and urine
tests, which confirmed that they did not present with any acute or
chronic medical and psychological conditions. None of the
subjects were extreme morning or evening types [47].
Subjects who participated in the study were non-smokers with a
body mass index (BMI) between 19 and 30 kg/m2 (23.562.9).
Subjects were included if they were not engaged in shift work,
transmeridian travel or unusual sleep/wake routines in the two
months prior to the study. Sleep health was confirmed with the
first night of laboratory PSG and questionnaires [47,48].
Circadian phase position was assessed with a morningness/
eveningness questionnaire [47], which was completed during
pre-study screening.
During the week prior to the laboratory phase of the study, all
subjects were monitored at home with actigraphy and sleep-wake
diaries. Subjects were instructed to avoid using caffeine, alcohol,
tobacco and medications for a minimum of one week before the
laboratory experiment. Compliance was verified by blood and
urine screens.
Of the original 16 subjects deemed eligible for the study, one did
not commence the study due to work commitments, and another
Restricted Sleep and Metabolism
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41218
elected to leave the laboratory prior to completion for personal
reasons, leaving a final sample size of N= 14.
Experimental Protocol
Subjects were studied in groups of 3 or 4 at a time for 9
consecutive days in the Centre for Sleep Research at the
University of South Australia. All subjects underwent two initial
nights of baseline sleep of 10 h TIB (B1, B2; 22:00–08:00),
followed by 5 nights of 4 h TIB (SR1–SR5; 04:00–08:00), and a
recovery night of 10 h TIB (R1; 22:00–08:00). Subjects left the
laboratory mid-morning following R1. All subjects completed the
same protocol. Trained research staff monitored subjects contin-
uously during the study period to ensure compliance with the
experimental protocol. Subjects also had daily contact with the
Principal Investigator.
During wake periods, subjects completed a driving simulation
task and neurobehavioral test batteries consisting of questionnaires
and cognitive performance tests. VASs for hunger, appetite and
satiety were completed daily. On B1 and SR5, these scales were
completed at 11:00, 12:30, 16:30 and 19:30. Subjects rated their
hunger (1 = ‘not hungry at all’ to 9= ‘as hungry as I’ve ever felt’),
appetite (1 = ‘very weak desire to eat’ to 9 = ‘very strong desire to
eat’) and satiety (1 = ‘not at all full’ to 9= ‘as full as I’ve ever felt’).
The other questionnaires and cognitive performance tests will be
reported elsewhere.
When not engaged in tasks, subjects were allowed to watch
movies, interact with each other and with study staff, and engage
in activities, such as card games and board games. While able to
move freely inside the laboratory, subjects were told that vigorous
exercise, or games which involved excess movement, were not
permitted.
Subjects wore a wrist actigraph throughout the 9-day laboratory
protocol. On B1, B2, SR2, SR3, SR5 and R1 sleep was recorded
with PSG using a standard montage. On all days except those with
blood draws (B1, SR5), subjects were given the opportunity to
shower between 08:30 and 09:30. The light levels in the laboratory
were kept at less than 20 lux during wake periods and less than 1
lux (lights off) during sleep periods. Ambient temperature was
maintained between 22uC and 24uC.
Food Consumption
Food intake was controlled during the laboratory phase of the
study. Subjects chose preferred food items from a limited menu
prior to entering the laboratory, but serving sizes and access to
food (timing and duration) was determined by the research team to
ensure consistency across days and subjects. Target energy intake
was 2000 kcal per day. Subjects ate an identical meal for breakfast,
lunch and dinner on SR5 to what they consumed on B1.
Blood Sampling and Continuous Glucose Monitoring
Blood draws were conducted on B1 and SR5 by two clinical
nurses. An intravenous 16G catheter was inserted at 08:15 into the
cubital fossa vein, and removed at approximately 20:30 the same
day. Seven blood draws occurred over the day, with approxi-
mately 15 ml collected per draw (5 ml for serum and 10 ml for
plasma) using BD VacutainerH blood collection tubes. The
maximum volume of blood taken per day was 105 ml. Pre-
prandial blood was drawn at 09:00, after which subjects consumed
a set breakfast. Blood was then drawn at 10:00, 12:00, 14:00,
16:00, 18:00 and 20:00. Blood samples were immediately cold
centrifuged. Serum and plasma were stored in 1.5 ml aliquots,
frozen at 220uC, and batched for assaying.
The Medtronic GuardianH REAL-Time Continuous Glucose
Monitoring System was used to monitor interstitial glucose for
24 h at baseline and after sleep restriction. The monitoring system
consisted of a 5 mm, hair-like sensor, which was inserted
subcutaneously 5 cm to the right of the navel, and a recording
device worn on the belt. Interstitial glucose levels were recorded
every 5 min. The sensor was calibrated every 2 h with capillary
blood, using the Accu-check Softclix Lancing Device LD01,
Optium glucose electrode test strips and Optium Xceed Blood
Glucose Meter. The sensor was tolerated well by all subjects. The
Medtronic GuardianH REAL-Time has been validated against
plasma glucose [49] and is widely used in clinical settings [50,51].
Assays
Plasma glucose was measured on a Hitachi 912 Chemistry
analyzer by the hexokinase method using kits from Roche
Diagnostics (Castle Hill, NSW, Australia). Plasma insulin (HI-
11K) and leptin (HL-81K) were assayed by radioimmunoassay
(RIA) according to the manufacturer’s instructions using kits
obtained from Millipore (Billerica, MA, USA). The intra-assay
coefficients of variation (CV) were below 10% for both assays.
Serum concentrations of triglycerides were measured with the
Siemens Advia 1650 Clinical Chemistry System (Siemens
Healthcare Diagnostics, Regency Park, SA, Australia). Total
testosterone and sex hormone binding globulin concentrations
were determined in serum using the Cobas electrochemilumines-
cence immunoassay (Roche Diagnostics Ltd., Indianapolis, IN,
USA) on the Roche Modular E170 (Roche Diagnostics Ltd,
Indianapolois, IN, USA). For sex hormone binding globulin
(SHBG) measurement, serum was diluted 1:21 by adding provided
SHBG diluents. The CV was 9.3% at a concentration of
10.7 nmol/l for total testosterone and 4.0% at a concentration
of 32.3 nmol/l for SHBG. Serum ACTH and cortisol were
assayed by RIA in a single run according to the manufacturer’s
instructions on the Immulite 1000 (Siemens Healthcare Diagnos-
tics, Regency Park, SA, Australia). This included ensuring supplied
quality control samples were within the acceptable ranges prior to
each run.
Statistical Analysis
Analyses were performed using SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA). Mixed-effects ANOVAs were conducted to test
effects of sleep restriction on metabolic and hormonal profiles.
Condition (B1, SR5), time of day (09:00, 10:00, 12:00, 14:00,
16:00, 18:00, 20:00) and condition*time of day interaction were
specified as fixed effects, and a random effect on the intercept was
included. Planned contrasts were conducted for ACTH and
cortisol to specifically examine the afternoon and early evening
period as previous studies found elevation of these hormones
during these times after sleep restriction.
Results
Fourteen male subjects completed the study. Of the original 16
subjects deemed eligible for the study, one did not commence the
study due to work commitments, and another elected to leave the
laboratory prior to completion for personal reasons.
Sleep Architecture
Polysomnography (PSG) was conducted on B1 (10 h TIB) and
SR5 (4 h TIB). As expected, total sleep time (TST) was reduced on
SR5 (mean 6 SD: 233.661.1 min) compared with B1
(519.468.9 min, F1,13 = 1034.6, p,0.001). Reductions following
sleep restriction were also found for sleep onset latency
(B1= 8.961.9 min; SR5= 0.660.2 min, F1,13 = 19.2, p,0.001),
and wake after sleep onset (B1= 55.568.6 min;
Restricted Sleep and Metabolism
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SR5=6.865.1 min, F1,13 = 33.3, p,0.001). Time spent in Stage 1
(B1= 10.562.5 min; SR5= 2.760.8 min, F1,13 = 15.5, p=0.002),
and Stage 2 (B1= 243.060.4 min; SR5= 70.065.3 min,
F1,13 = 308.8, p,0.001) were likewise reduced on SR5. Time
spent in slow wave sleep was reduced in SR5
(B1= 129.2610.8 min; SR5=95.666.7 min, F1,13 = 18.4,
p,0.001). Minutes spent in REM sleep were also reduced
following sleep restriction (B1= 136.668.3 min;
SR5=65.365.1 min; F1,13 = 61.9, p,0.001).
Caloric Intake
Food consumption was strictly controlled throughout the study.
Subjects consumed identical meals on B1 and SR5. Average
caloric intake (mean 6 SD) was 1973.0631.9 kcal on B1 and
1961.8630.9 kcal on SR5. Carbohydrates accounted for
52.9%62.2% of caloric intake on B1 and 52.7%62.3% on
SR5; fats accounted for 26.9%61.5% of caloric intake on B1 and
27.1%61.7% on SR5; and proteins accounted for 16.8%60.8%
of caloric intake on B1 and 16.960.9% on SR5.
A summary of the results of the mixed-effects ANOVAs for all
blood measures can be found in Table 1.
Adrenal Axis - Adrenocorticotropic Hormone (ACTH) and
Cortisol
Mean ACTH (Figure 1A) decreased across time of day on both
B1 and SR5, demonstrating a normal diurnal pattern (p,0.001).
ACTH was 3.2% higher after sleep restriction (mean 6 SE
22.161.1 pg/ml) than at baseline (21.561.6 pg/ml), but this
increase was not statistically significant (p=0.59). No condition*-
time of day interaction was found (p=0.94). These results are
summarized in Table 1. Previous studies have shown largest
differences between baseline and sleep restricted levels of both
ACTH and cortisol to be in the late afternoon. The greatest
difference between B1 and SR5 ACTH in the present data was
observed between 16:00 and 20:00. Planned contrasts were
conducted on ACTH and cortisol (results for cortisol reported
below) as previous studies have shown that sleep restriction
prevents the usual afternoon and evening drop in these hormones.
The analysis revealed that ACTH levels were higher at 16:00 on
SR5 (mean 6 SEM; 20.261.4) than B1 (16.861.5; F1,97 = 4.7,
p=0.03), but not at 18:00 (SR5: 19.362.3, B1: 16.461.4;
F1,97 = 1.5, p=0.22) or 20:00 (SR5: 13.561.0, B1: 13.461.0;
F1,97 = 0.02, p=0.88).
Mean cortisol (Figure 1B) decreased across time of day on both
B1 and SR5, reflecting the normal diurnal rhythm in cortisol
(p,.001). Cortisol was 15.5% higher after sleep restriction (mean
6 SE: 337.4616.9 nmol/L) than at baseline (292.2618.1), and
this increase was statistically significant (p=0.002). No condi-
tion*time of day interaction was found (p= .35). There was an
increase in cortisol between 16:00 and 20:00 following sleep
restriction compared with baseline. Planned contrasts showed that
cortisol levels were significantly higher at 16:00 on SR5 (mean 6
SEM; 247.1621.9) than B1 (179.0616.6; F1,97 = 5.5, p=0.02) and
at 18:00 (SR5: 298.0641.4, B1: 178.1617.9; F1,97 = 13.3,
p,0.001). No significant difference was found between SR5
(188.3625.9) and B1 (132.2613.2) at 20:00 (F1,97 = 2.9, p=0.09).
Glucose Metabolism - Glucose, Insulin and Triglycerides
Mean blood glucose (Figure 1C) decreased across time of day on
both B1 and SR5, reflecting the normal diurnal rhythm in glucose
(p,0.001). Glucose was 11.4% higher after sleep restriction (mean
6 SE; 5.560.1) than at baseline (4.960.1), and this increase was
statistically significant (p,0.001). A condition*time of day
interaction was also found, which was indicative of an amplified
response to meals after sleep restriction (p,.001). Figure 2 shows
breakfast pre-prandial (09:00) and post-prandial (10:00) plasma
glucose at B1 and SR5. There was a difference between pre- and
post-prandial glucose on B1 (p,.001), and between pre- and post-
prandial glucose on SR5 (p,.001). There was no difference
between pre-prandial glucose on B1 and SR5 (p=0.13), but there
was between B1 and SR5 post-prandial glucose (p,.001),
suggesting an impaired response to ingestion of the breakfast
meal following sleep restriction (see Figure 2). Fasting homeostatic
model assessment (HOMA) did not change significantly on SR5
(mean 6 SE; 2.961.2) compared with B1 (2.661.1, p=0.18).
However, a difference was found between B1 and SR5 HOMA
across the day (p,0.001), with time of day (p,0.001) and
condition*time of day effects also found (p,0.001).
Elevated glucose was also seen in interstitial fluid (Figure 3).
Interstitial glucose after sleep restriction was elevated compared
with baseline (F1,7596 = 618.4, p,0.001), and a significant time of
day effect was also found (F312,7596 = 6.0, p,0.001). No con-
dition*time of day interaction was found (F312,7596 = 1.1, p=0.20).
Mean insulin (Figure 1D) decreased across time of day on both
B1 and SR5 (p,0.001). Insulin was 28.8% higher after sleep
restriction (mean 6 SE: 44.264.2 uU/ml) than at baseline
(34.462.8), and this increase was statistically significant
(p,0.001). A condition*time of day interaction was also found,
and appeared to be indicative of an amplified response to meals
after sleep restriction (p=0.001).
Mean triglycerides (Figure 1E) increased across time of day on
both B1 and SR5, peaking at 16:00, and reflecting significant
change in levels across the day (p,0.001). Triglycerides were
11.0% lower after sleep restriction (mean 6 SE: 1.3760.1 mmol/
l) than at baseline (1.5360.0), and this decrease was statistically
significant (p=0.007). No significant condition*time of day
interaction effect was found (p=0.97).
Leptin
Mean leptin (Figure 1F) increased across time of day on both B1
and SR5, reflecting normal rhythm (p,0.001). Leptin was 13.7%
higher after sleep restriction (mean 6 SE: 4.860.4 ng/ml) than at
baseline (4.360.3), and this increase was significant (p=0.001). No
condition*time of day interaction effect was found (p=0.80).
Testosterone and Sex Hormone Binding Globulin (SHBG)
Total testosterone (Figure 1G) decreased across time of day on
both B1 and SR5, reflecting testosterone’s normal diurnal rhythm
(p,0.001). No significant effect of condition (p=0.09), or
condition*time of day interaction (p=0.85) was found.
Sex hormone binding globulin (SHBG; Figure 1H) did not show
any time of day effects (p=0.21). SHBG was 11.0% lower after
sleep restriction (mean 6 SE: 27.961.0 nmol/L) than at baseline
(31.461.2) and this decrease was significant (p,0.001). No
condition*time of day interaction effect was found (p=0.86).
Self-Reported Hunger, Appetite and Satiety
Subjects completed hunger, appetite and satiety visual analogue
scales (VAS) on B1 and SR5. No changes were seen following sleep
restriction in self reported hunger (F1,87 = 0.5, p=0.49), appetite
(F1,87 = 0.01, p=0.92), or satiety (F1,87 = 0.2, p=0.68), although a
time of day effect was apparent for all variables (hunger
(F3,87 = 19.9, p,0.001); appetite (F3,87 = 14.9, p,0.001); satiety
(F3,87 = 20.9, p,0.001)).
Restricted Sleep and Metabolism
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Discussion
Previous studies have shown impaired glucose metabolism
following sleep restriction, a finding which is reflected in elevated
glucose and insulin in the present study. This is possibly due to a
rise in afternoon cortisol reflecting adrenal axis activation. Leptin
levels also increased in an environment of adequate energy intake
and reduced energy expenditure, but this increase did not lead to
changes in appetite or hunger. This is in contrast to other
published findings in the field which have previously documented
decreases in leptin and increases in hunger and appetite following
sleep restriction [17,19]. A key difference between these studies
and the present study was the inclusion of strict caloric control
across the entire study duration which suggests that in the context
of appropriate caloric intake, leptin levels are not significantly
affected adversely by sleep restriction.
This is one of the first studies to examine the direct effect of
sleep restriction on testosterone and sex hormone binding globulin
(SHBG), which have both been linked in epidemiological findings
with metabolic syndrome and insulin resistance. While testoster-
one did not change significantly with sleep restriction, a trend was
observed, with levels reduced on SR5 compared to B1. SHBG
decreased following sleep restriction, possibly due to increases in
insulin which down-regulates SHBG [52]. These data have
implications for healthy metabolic functioning.
It has been hypothesised that sleep restriction may elicit a
physiological stress response that activates the hypothalamo-
pituitary-adrenal (HPA) axis, increasing circulating cortisol.
Chronically high levels of cortisol can impair insulin sensitivity
and disrupt glucose metabolism, increasing the risk for type 2
diabetes. While a number of studies have found that sleep
restriction does not increase overall mean cortisol
[15,16,21,45,53], several others have found elevated cortisol in
the latter part of the day instead of the usual diurnal decline
[17,18,54]. Raised cortisol concentrations in the evening are
Table 1. Statistical results from mixed-effects ANOVAs for all metabolic and hormonal variables.
Regression Output
Variable B1 SR5 F DFNUM DFDENOM p
ACTH 21.5(1.6) 22.1(1.1) Condition 0.3 1 168 .59
(pg/ml) Time of Day 15.2 6 168 ,.001
Condition*Time of Day 0.3 6 168 .94
Cortisol 292.2(18.1) 337.4(16.9) Condition 10.2 1 168 .002
(nmol/l) Time of Day 48.6 6 168 ,.001
Condition*Time of Day 1.1 1 168 .35
Glucose 4.9(0.1) 5.5(0.1) Condition 25.3 1 168 ,.001
(mmol/l) Time of Day 11.6 6 168 ,.001
Condition*Time of Day 4.8 6 168 ,.001
Insulin 34.4(2.8) 44.2(4.2) Condition 12.2 1 168 ,.001
(uU/ml) Time of Day 37.4 6 168 ,.001
Condition*Time of Day 3.9 6 168 .001
Triglycerides 1.5(0.1) 1.4(0.1) Condition 7.5 1 168 .007
(mmol/l) Time of Day 12.7 6 168 ,.001
Condition*Time of Day 0.2 6 168 .97
Leptin 4.3(0.3) 4.8(0.4) Condition 10.7 1 168 .001
(ng/ml) Time of Day 9.8 6 168 ,.001
Condition*Time of Day 0.5 6 168 .80
Testosterone 14.7(0.5) 14.0(0.5) Condition 2.8 1 168 .09
(nmol/l) Time of Day 11.2 6 168 ,.001
Condition*Time of Day 0.5 6 168 .85
SHBG 31.4(1.2) 27.9(1.0) Condition 12.1 1 168 ,.001
(nmol/l) Time of Day 1.4 6 168 .21
Condition*Time of Day 0.4 6 168 .86
HOMA 8.3(0.8) 12.1(1.3) Condition 19.3 1 168 ,.001
Time of Day 35.1 6 168 ,.001
Condition*Time of Day 5.4 6 168 ,.001
Note: Results from the Linear Mixed Models Analysis are shown including the mean (6 SE) values from B1 and SR5, F value, numerator degrees of freedom (DFNUM),
denominator degrees of freedom (DFDENOM) and significance (p) values. ACTH, adrenocorticotropic hormone; SHBG, sex hormone binding globulin; HOMA, homeostatic
model assessment. ‘Condition’ refers to a difference between B1 and SR5, while ‘Time of Day’ refers to the change over the day of blood sampling. There was a
significant day effect (B1 compared with SR5) for cortisol, glucose, insulin, triglycerides, leptin and sex hormone binding globulin. A trend for decreasing testosterone
was found. A significant draw effect (change in levels within B1 and SR5) was found for ACTH, cortisol, glucose, insulin, triglycerides, leptin and testosterone. Day by
draw interactions were found for glucose and insulin. pg/ml, picogram per milliliter; nmol/l, nanomol per liter; mmol/l, millimol per liter; uU/ml, micromoles per milliliter;
and ng/ml, nanograms per milliliter.
doi:10.1371/journal.pone.0041218.t001
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thought to contribute to age-related insulin resistance [55,56].
This is consistent with the current study which found that cortisol
was elevated in the afternoon and evening and supports the
hypothesis that sleep restriction may mimic pathophysiological
processes that occur with ageing and lead to chronic age-related
diseases such as type 2 diabetes and cardiovascular disease [18].
ACTH did not change with sleep restriction in the current study,
but the levels were significantly decreased in the afternoon at
16:00, in a similar pattern to cortisol. These findings are unlikely to
be a consequence of phase shift in circadian rhythms, as no
Figure 1. Metabolic and hormonal outcomes on baseline day 1 (B1) and after 5 nights of sleep restriction (SR5). Mean levels of: A–
ACTH, B–cortisol, C–glucose, D–insulin, E–triglycerides, F–leptin, G–total testosterone, and H–sex hormone binding globulin. Bars represent SE. All
subjects experienced two baseline nights of 10 h TIB first; the dashed grey curve shows data from the first baseline day (B1). Subjects then underwent
5 nights of sleep restriction to 4 h TIB; the solid black curve shows data from the last sleep-restricted day (SR5). On each of these two days, blood was
drawn at 09:00 (fasting) and then every 2 h from 10:00 to 20:00. Vertical dashed grey lines represent meal opportunities; B, breakfast; L, lunch; D,
dinner.
doi:10.1371/journal.pone.0041218.g001
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observable shifts in the peak or trough of hormonal measures were
evident following sleep restriction.
Consistent with previous research [15,18–20], this study found
that glucose tolerance to meals was impaired and insulin increased
following sleep restriction suggesting that it may induce an insulin
resistant state in healthy men. However, HOMA insulin resistance
was not significantly different between B1 and SR5, suggesting
that hepatic insulin sensitivity was not influenced by sleep
restriction, although subtle changes in insulin resistance would
not be detected by the HOMA method. The significant
condition*time of day interaction in HOMA calculations suggest,
but do not prove, potential postprandial effects. Such calculations
when used after an oral glucose tolerance test form the basis for
the Matsuda insulin resistance index, which is known to reflect
peripheral, rather than hepatic, insulin sensitivity [57]. Our data
suggest that peripheral rather than hepatic insulin resistance is
induced with sleep restriction. If true, impaired peripheral insulin
resistance in the presence of raised glucose as reported here would
only occur with concomitant reduction in pancreatic beta cell
function. Such a change is plausible [58–61], however we did not
directly assess pancreatic beta cell function.
The finding of increased insulin following sleep restriction in the
present study is in contrast to some previous findings. Of the
previous studies that did not find changes in insulin [18,19,23],
one allowed subjects to leave the laboratory during the day,
thereby reducing control over snacking and naps [18], while
another study used glucose tolerance tests [23]. These tests involve
fasting and consumption of a glucose bolus which may impact
glucose metabolism differently to the more naturalistic approach
used in the current study where the focus was on the glucose and
insulin response to meals and general changes in these outcomes
after sleep restriction. Interestingly, no difference was observed
between baseline and sleep restricted fasting glucose or insulin
which, when also taking into consideration the marked response to
meals, may indicate that sleep restriction impacts hepatic versus
muscle glucose metabolism differentially. Further study is needed
to examine this possibility.
The current study also utilized continuous glucose monitoring,
which frequently sampled glucose for 24 h in the interstitial fluid
at baseline and then after sleep restriction. This technology is
unique as it is unobtrusive and enables long term monitoring of
glucose with low burden to the study participant. Interstitial
glucose followed a similar pattern to blood glucose in response to
sleep restriction, with elevated interstitial glucose levels after meals
Figure 2. Blood glucose levels before and after breakfast on
baseline day 1 (B1) and after 5 nights of sleep restriction (SR5).
Mean pre-prandial (dark grey) and post- prandial (light grey) blood
glucose (mmol/l) at baseline (B1) and following sleep restriction (SR5) (*,
p= .002, **, p,.001) (bars = SE).
doi:10.1371/journal.pone.0041218.g002
Figure 3. 24 h interstitial glucose (mmol/l) on baseline day 1 (B1) and after 5 nights of sleep restriction (SR5). Readings were taken at
5 min intervals starting at 20:00 using the GuardianH REAL-Time Continuous Glucose Monitoring System. Meal times are marked with arrows, left to
right: breakfast (B) (09:00), lunch (L) (13:00), and dinner (D) (18:30). Baseline day 1 interstitial glucose is shown in grey; sleep restriction day 5 is shown
in black (bars = SE).
doi:10.1371/journal.pone.0041218.g003
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and during the night-time period. The importance of this finding is
twofold – it suggests that interstitial monitoring provides an
accurate reflection of glucose levels from venous samples, and
indicates the importance of continuous monitoring over nocturnal
periods to truly unveil the effect of sleep restriction on glucose.
This technology can be tolerated for extended periods of time and
may be a useful tool in future studies to evaluate the cumulative
effects of sleep restriction and/or displacement on glucose.
This study provided novel insight into the relationship between
sleep restriction and SHBG, the glycoprotein predominantly
responsible for the transport of testosterone. Following sleep
restriction, SHBG levels were significantly reduced. This is
particularly relevant to the relationship between sleep restriction
and glucose metabolism, as low levels of endogenous SHBG have
been linked with poor glucose tolerance [62,63], and conversely,
higher levels associated with reduced risk of type 2 diabetes
[63,64].
To our knowledge this was also the first study to examine the
impact of sleep restriction on triglycerides in men. While cohort
data have suggested that shorter sleep duration is associated with
higher triglyceride levels [24], no experimental research has
examined the impact of sleep restriction on triglycerides in men
after more than two nights of sleep restriction. There have been
some experimental investigations of FFA. These studies found that
fasting FFA were unchanged after one night of sleep restriction
[15], and significantly increased after two nights of sleep restriction
[16] to 4 h TIB. In the current study triglycerides decreased
following sleep restriction. This decrease could be due, in part, to
differences in the study subjects’ diet prior to the laboratory phase
of the study. As diet was not monitored prior to the laboratory
phase of the study (with the exception of alcohol and caffeine
consumption, which was not allowed), it is not known if subjects
routinely ate more fats and carbohydrates than they consumed
during the laboratory phase of study. Triglycerides are known to
increase with a carbohydrate rich diet, and also decrease when
dietary intake of refined carbohydrates is reduced [65]. The
macronutrients of the diet during the laboratory phase of the study
were balanced and subjects were provided with a range of foods
including salads and quality protein. A rapid change in their diet,
including a reduction in the amount of carbohydrates consumed,
relative to habitual food intake could have produced the small
decrease in triglycerides observed in the present study. As such, the
change in triglycerides may not represent a change that would
occur outside the laboratory environment.
Early experimental studies exploring the relationship between
sleep restriction and the adipose-derived hormone leptin found
decreases after both two [19] and six [17] nights of sleep restriction
to 4 h TIB. In one study, these decreases were aligned with self
reported increases in hunger and appetite [19]. This prompted the
hypothesis that sleep restriction is linked with obesity via
disruption of leptin and increased cravings for carbohydrate rich
foods [17]. However energy intake was restricted in these studies
which may have resulted in an increased leptin response to the
restricted calories rather than a direct effect of sleep restriction on
leptin [35]. In more recent investigations, in which subjects were
either allowed BMI-appropriate food intake or ad libitum food
access, leptin was unaffected [30,32,66] or elevated [20,29,31].
The current study found a significant increase in leptin
following sleep restriction in line with these and recent cohort
[67] studies. In the present study, food was controlled to an
appropriate caloric intake for subjects’ weight, height, age and
activity level and subjects did not report significant changes
following sleep restriction in hunger, appetite and satiety. Time of
day effects apparent in this self-report data are unsurprising given
the timing of test bouts pre lunch and post dinner. The leptin
increase seen in our data was likely due to the adequate energy
intake and the sedentary lifestyle subjects experienced in the
laboratory, suggesting little change in overall energy balance.
However, if calories are restricted during sleep loss it seems that
leptin will decrease to help correct the energy imbalance and
protect against changes in nutrient supply. The link between sleep
loss and obesity therefore appears more complicated than a simple
disruption of leptin metabolism.
The effect of sleep restriction on testosterone has received little
attention, despite the fact that the majority of experimental sleep
restriction and metabolic studies have been conducted in men.
Research on the relationship between sleep and testosterone has
predominantly focused on the effect of total sleep deprivation
[43,44,68], or examined the differential effects of sleep stages on
testosterone [69–73]. Given the relationship between total sleep
time and morning testosterone [72], it is unsurprising that the only
published data to date on the relationship between sleep restriction
and testosterone found that levels decreased significantly after 8
nights of 5 hours time in bed [45]. While testosterone did not
decrease following sleep restriction in the current study, there was
a clear trend, consistent with recent findings [45]. The timing and
the duration of the sleep restriction period differed considerably
between the two studies (8 nights of 5 h TIB, 12:30–05:30 [45]
versus 5 nights of 4 h TIB, 04:00–08:00) and it is possible, because
of the relationship that testosterone has with total sleep time as well
as its circadian variability, that greater periods of sleep loss or loss
of certain sleep stages, such as REM sleep, are needed to observe
an effect. These results are especially important for older men who
regularly restrict their sleep. Testosterone decreases with age and
the further insult of chronically reduced sleep could have
important implications for health status, given the role of
testosterone in a number of physical and psychological conditions
such as sexual function [74], muscle and bone mass [75], and
mood [76].
While this study was limited to male participants, a low SHBG
has also been shown to be associated with obesity [77,78], insulin
resistance [78,79], and the metabolic syndrome in women [80].
SHBG is a marker of de novo hepatic lipogenesis in both men and
women [81,82]. The apparent contradiction that low testosterone
levels are associated with insulin resistance and the metabolic
syndrome in men when the association is with high testosterone
levels in women is the result of the decrease in SHBG and its
consequent effect on the assessment of testosterone in each sex
[81].
The results of this study should be considered in light of several
methodological constraints. After the fasting blood draw, blood
sampling occurred at approximately 2 hourly intervals across B1
and SR5 and did not include nocturnal sampling. This means that
fluctuations in between the blood draws were not captured, and
makes it difficult to compare with studies that sampled blood more
frequently. Further, it does not enable comment on nocturnal
patterns of hormonal levels. This study was also only able to
sample blood before and after sleep restriction at one particular
dose, and so the dose-response (sleep restriction dose and number
of days of exposure) aspects of the effects of sleep restriction on
metabolic and hormonal measures cannot be determined.
Finally, as with the majority of laboratory-based studies of sleep
restriction and metabolic regulation, this study only investigated
healthy, young adult, male subjects, and findings may not
generalize to women, to other age categories, and to clinical
populations. Nevertheless, this study is the first to examine the
effect of sleep restriction on glucose, insulin, triglycerides and
potentially underlying hormonal mechanisms in concert. Our
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findings indicate that short term sleep curtailment leads to changes
in glucose metabolism and adrenal reactivity. When experienced
chronically, these changes may increase the risk for type 2
diabetes.
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